New hope for fighting tough pancreatic tumors
NCT ID NCT05325281
Summary
This early-stage study tested a new drug called CPI-613 (devimistat) when given alongside standard chemotherapy and radiation for inoperable pancreatic cancer. The main goal was to find the highest safe dose of the new drug combination and check for side effects. Researchers hoped adding CPI-613 would help the standard treatment work better to control the local tumor.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREAS ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Froedtert & the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
Conditions
Explore the condition pages connected to this study.